Reported 16 days ago
This year, Summit Therapeutics has seen a staggering 900% increase in stock value, significantly outpacing Nvidia's impressive 137% rise, thanks to its promising cancer drug ivonescimab, which recently excelled in a clinical trial. While Summit is drawing attention for its potential, investors should be cautious given its high valuation and the risks involved in biotechnology investing.
Source: YAHOO